相关实验视频
Updated: Jul 30, 2026
10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
20.9K
用纤维细胞生长因子装载的基托桑衍生基微球用于治疗糖尿病
Jue Wu1, Qian Chen1, Wenfei Wang2
1College of Chemistry and Material Sciences, School of Life Science, Heilongjiang University, Harbin 150080, China.
Polymers
|July 29, 2023
概括
新的微球封装了糖尿病的蛋白质药物,提供了一个稳定的,双口服和注射输送系统. 这项创新解决了当前胰岛素治疗的局限性,为血糖控制提供了一个有希望的替代方案.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 内分泌学 在内分泌学.
背景情况:
- 2型糖尿病 (T2DM) 的特点是高血糖,胰岛素注射作为主要治疗方法,面临抗性和副作用等挑战.
- 基于蛋白质的药物,如纤维细胞生长因子-21 (FGF-21) 显示出对血糖控制的希望,但患有不稳定性,限制了它们的临床使用.
研究的目的:
- 为蛋白质低血糖药物开发一个稳定,多功能的纳米输送系统.
- 通过封装在基于奇托的新型微球中,增强FGF-21类型的治疗潜力.
- 评估开发的系统对口服和注射药物的疗效.
主要方法:
- 纤维细胞生长因子-21模拟物 (NA-FGF) 被封装在N-2-Hydroxypropyl trimethyl氨基化基/碳氧甲基基 (N-2-HACC/CMCS) 纳米材料中.
- 用NA-FGF装载的N-2-HACC/CMCS微球的制备 (NA-FGF-N-2-HACC/CMCS MPs).使用NA-FGF制成的N-2-HACC/CMCS微球.
- 进行了体外和体内研究,以评估生物相容性,生物稳定性,药物释放和低血糖疗效.
主要成果:
- 准备好的NA-FGF-N-2-HACC/CMCSMP显示出极好的生物相容性和生物稳定性.
- 这些微球表现出持久的药物释放能力.
- 在体外和体内实验证实了微球通过口服和注射途径有效调节低血糖.
结论:
- NA-FGF-N-2-HACC/CMCS MPs代表了对低血糖药物的有希望的通用纳米输送系统.
- 开发的微球为口服和注射提供了稳定有效的平台,克服了当前蛋白质药物配方的局限性.
更多相关视频
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.3K
05:26Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications
Published on: April 13, 2022
3.5K
相关概念视频
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...